You are here:
| Reference : Thymic self-antigen expression for the design of a negative/tolerogenic self-vaccine aga... |
| Scientific journals : Article | |||
| Human health sciences : Endocrinology, metabolism & nutrition Human health sciences : Immunology & infectious disease | |||
| http://hdl.handle.net/2268/82718 | |||
| Thymic self-antigen expression for the design of a negative/tolerogenic self-vaccine against type 1 diabetes | |
| English | |
| Alami Chentoufi [ > > ] | |
Geenen, Vincent  [Université de Liège - ULg > > Centre d'immunologie - Embryologie >] | |
| Jul-2011 | |
| Clinical & Developmental Immunology | |
| Hindawi Publishing Corporation | |
| International | |
| 1740-2522 | |
| 1740-2530 | |
| [en] Thymus ; Type 1 diabetes ; Insulin-like growth factor 2 ; Insulin ; AIRE ; Self-vaccination | |
| [en] Before being able to react against infectious non-self antigens, the immune system has to be educated in the recognition and tolerance of neuroendocrine proteins and this critical process takes place only in the thymus. The development of the autoimmune diabetogenic response results from a thymus dysfunction in programming central self-tolerance to pancreatic insulin-secreting islet β cells, leading to the breakdown of immune homeostasis with an enrichment of islet β-cell reactive effector T cells and a deficiency of β-cell specific natural regulatory T cells (nTregs) in the peripheral T-lymphocyte repertoire. Insulin-like growth factor 2 (IGF-2) is the dominant member of the insulin family expressed during fetal life by the thymic epithelium under the control of the autoimmune regulator (AIRE) gene/protein. Based on the close homology and cross-tolerance between insulin, the primary T1D autoantigen, and IGF-2, the dominant self-antigen of the insulin family, a novel type of vaccination, so-called “negative/tolerogenic self-vaccination”, is currently being developed for prevention and cure of T1D. If this approach were found to be effective for reprogramming immunological tolerance in T1D, it could pave the way for the design of other self-vaccines against autoimmune endocrine diseases, as well as other organ-specific autoimmune diseases. | |
| Fonds de la Recherche Scientifique (Communauté française de Belgique) - F.R.S.-FNRS ; Région wallonne : Direction générale des Technologies, de la Recherche et de l'Energie - DGTRE ; EASD ; Union Européenne = European Union - UE = EU | |
| Researchers ; Professionals | |
| http://hdl.handle.net/2268/82718 |
| File(s) associated to this reference | ||||||||||||||
|
Fulltext file(s):
| ||||||||||||||
All documents in ORBi are protected by a user license.
